MEsenchymal StEm Cells for Multiple Sclerosis

You may be eligible if

• Age 18 to 50 years
• Disease duration 2 to 10 years (included)
• Diagnosis of MS
• Relapsing remitting MS (RRMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by one or more of the following:
• more or egal 1 clinically documented relapse in past 12 months
• more or egal 2 clinically documented relapses in last 24 months
• more or egal 1 GEL at MRI performed within the last 12 months
• Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by both::
• With more or egal 1 clinically documented relapse in the last twelve months
• Without on-going relapses, but with more or egal 1 GEL at MRI performed within the last 12 months.
• Primary progressive MS (PPMS) patients with all the following features:
• an increase ofmore or egal 1 EDSS point (if at inclusion EDSS inferior or egal 5.0) or 0.5 EDSS point (if at inclusion EDSS more or egal 5.5), in the last twelve months
• more or egal 1 GEL at MRI performed within the last 12 months
• Positive cerebrospinal fluid (CSF) (oligoclonal banding).
• * EDSS (Expanded Disability Status Scale) 3.0 to 6.5
• * Women of childbearing age with an effective contraception.
• Inferior to 3 months since treatment with any immunosuppressive therapy including natalizumab and fingolimod
• Inferior or egal to 1 month since last treatment with interferon-beta or glatiramer acetate
• Corticosteroid treatment Inferior or egal to 30 days
• Relapse inferior or egal to 60 days
• Any active or chronic infection including infection with HIV1-2 (Human Immunodeficiency Virus 2) or HTLV I-II (Human T-lymphotropic virus I-II) or Syphilis or chronic Hepatitis B or Hepatitis C inferior to 1 month
• Previous history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year
• Severely limited life expectancy by another co-morbid illness
• History of previous diagnosis of myelodysplasia or previous hematologic disease or current clinically relevant abnormalities of white blood cell counts
• Pregnancy or risk or pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study)\*\*
• eGFR (estimated Glomerular Filtration Rate ) inferior to 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination.
• Inability to give written informed consent in accordance with research ethics board guidelines.